1. Considered and approved Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2025 along with the Limited review report; 2. Other routine businesses with the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Choksi Laboratories' Board approved unaudited financial results for Q2 and H1 FY26 on 14 November 2025. Revenue from operations for Q2 stood at ₹1,111.71 lakhs, up roughly 20% YoY from ₹926.22 lakhs, while H1 revenue rose about 12% YoY to ₹2,235.90 lakhs. Profit before tax for H1 nearly doubled to ₹118.99 lakhs (from ₹71.15 lakhs), and net profit grew about 26% YoY to ₹62.71 lakhs (from ₹49.62 lakhs). Basic EPS for H1 came in at ₹0.90 versus ₹0.71 last year. The statutory auditor Prateek Jain & Co. issued an unqualified (clean) limited review report. Net cash from operations for H1 was positive at ₹266.71 lakhs.
Strong profit growth on the back of expanding margins is a positive signal for shareholders, but the company's debt-to-equity ratio remains elevated at around 1.17x (total borrowings of about ₹2,856 lakhs against equity of ₹2,449 lakhs), which is a watch item. Overall, results are constructive for sentiment in the near term.